Frontiers in Oncology

OCT 23, 2026 · JOURNAL ARTICLE

Accelerator-based BNCT as a drug–device regimen: system engineering, clinical evidence, and regulatory considerations

Frontiers in Oncology

Boron neutron capture therapy (BNCT) is a binary, tumor-selective radiotherapy modality that combines preferential delivery of boron-10 to tumor tissue with neutron irradiation to

OCT 23, 2026 · REVIEW

The effectiveness of virtual reality–assisted relaxation therapy in improving psychological symptoms and fatigue of breast cancer survivors: a systematic review and meta-analysis

Frontiers in Oncology

Objective This meta-analysis investigated the effect of virtual reality–assisted relaxation therapy (VR-ART) on the reduction of psychological symptoms and fatigue in breast cancer

OCT 23, 2026 · JOURNAL ARTICLE

Case Report: Unicentric Castleman disease mimicking metastatic lymphadenopathy in a patient with a history of triple-negative breast cancer and angiomatoid fibrous histiocytoma

Frontiers in Oncology

Background Castleman disease (CD) is a rare and highly heterogeneous group of lymphoproliferative disorders. Its imaging manifestations may overlap with those of metastatic lymphad

OCT 23, 2026 · JOURNAL ARTICLE

Pathological complete response and long-term outcomes after neoadjuvant therapy for breast cancer: a multicenter retrospective cohort study with exploratory subtype analyses

Frontiers in Oncology

Background To examine differences in pathological complete response (pCR) rates across immunohistochemistry (IHC)-defined breast cancer surrogate subtypes and the association of pC

OCT 23, 2026 · JOURNAL ARTICLE

The role and mechanisms of ESM1 in tumors

Frontiers in Oncology

Endothelial cell-specific molecule-1 (ESM1, also known as endocan), is a sulfated proteoglycan primarily secreted by vascular endothelial cells, although it can also be expressed b

OCT 23, 2026 · JOURNAL ARTICLE

A comparison of 68Ga-PSMA PET/MR, 18F-FDG PET/CT and biochemical monitoring in neuroendocrine prostate cancer: a case report

Frontiers in Oncology

Neuroendocrine prostate cancer (NEPC) is a rare, aggressive subtype with hormonal resistance and poor prognosis. Traditional serum biomarkers such as prostate-specific antigen (PSA

OCT 22, 2026 · JOURNAL ARTICLE

The cervicovaginal microbiome as a candidate correlate and potential predictor of HPV clearance and treatment response after HSIL therapy: a scoping review

Frontiers in Oncology

Background Persistent high-risk human papillomavirus (hrHPV) infection causes virtually all high-grade squamous intraepithelial lesions (HSIL) and cervical cancer, but only a minor

OCT 22, 2026 · JOURNAL ARTICLE

Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review

Frontiers in Oncology

Icotinib significantly improves survival and prognosis in patients with epidermal growth factor receptor (EGFR)-sensitive non-small cell lung cancer (NSCLC). It is generally well-t